Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 15Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 7Carcinoma 2Neoplasms 1Lymphoma, Mantle-Cell 1Kidney Neoplasms 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Neoplasms × Axitinib × Clear all
NCT04033991 2023-04-06

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Pfizer

Completed
684 enrolled 20 charts
Tumor-Agnostic

Carcinoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡